ASMF Pro Learning Management System

This Project is to design and develop an online learning management system for students, which will be an open source learning management tools like blackboard, which will provide an online platform for conducting and taking classes online. Where students can register for the classes and get access to the online lectures provided by the instructor that can be in any file format. This system consists of a registration module where a new student can register and login. The students who got registered will get the access to register for the course. And instructor module has the separate registration and can have access to the student details and list of students registered for the course. The student module has student registration and login, at the registration page student need to provide with all the details like his name, email, phone number and it provide a student to add or drop a course and get access to the course description and details. The students can access the lectures in the portal provided by the instructor, the lecture can be in any type for example it can be a material or video or link to the source etc. The files can be of any format like pdf, doc, ppt, video etc. There will be an assignment submission portal or link where all the students can submit the assignment and can access their grades. The instructor module will have the different registration form and after login to their portal an instructor can have access to all the student details and list of students that has registered for the class and adding and removing a student. Instructor can send a notification email to all the students and can also notify through text messages via mobile phone. Instructor can provide the lecture through uploading and updating the materials and video lectures to the system so that all the students can access to the materials provided by the instructor. And the instructor can provide record on-screen activity to students for assist with software installation and course related support, with the help of screencast tools. Instructor has the portal to post the assignments and check the assignments posted by students and grade them

A review of the state of the art in non-contact sensing for covid-19

COVID-19, caused by SARS-CoV-2, has resulted in a global pandemic recently. With no approved vaccination or treatment, governments around the world have issued guidance to their citizens to remain at home in efforts to control the spread of the disease. The goal of controlling the spread of the virus is to prevent strain on hospitals. In this paper, we focus on how non-invasive methods are being used to detect COVID-19 and assist healthcare workers in caring for COVID-19 patients. Early detection of COVID-19 can allow for early isolation to prevent further spread. This study outlines the advantages and disadvantages and a breakdown of the methods applied in the current state-of-the-art approaches. In addition, the paper highlights some future research directions, which need to be explored further to produce innovative technologies to control this pandemic

Towards the Digital Twin (DT) of narrow-band Internet of Things (NBIoT) wireless communication in industrial indoor environment

A study of the behavior of NB-IoT wireless communication in an industrial indoor environment was conducted in this paper. With Wireless Insite software, a scenario in the industrial sector was simulated and modeled. Our research examined how this scenario or environment affected the communication parameters of NB-IoT’s physical layer. In this context, throughput levels among terminals as well as between terminals and transceiver towers, the power received at signal destination points, signal-to-noise ratios (SNRs) in the environment, and distances between terminals and transceivers are considered. These simulated results are also compared with the calculated or theoretical values of these parameters. The results show the effect of the industrial setting on wireless communication. The differences between the theoretical and simulated values are also established

An Efficient Deep Learning-based Spectrum Awareness Approach for Vehicular Communication

Constellation images of different wireless modulation orders (PSK and QAM

Chaos‐based privacy preserving vehicle safety protocol for 5G Connected Autonomous Vehicle networks

There is a high demand for secure and reliable communications for Connected Autonomous Vehicles (CAVs) in the automotive industry. Privacy and security are key issues in CAVs, where network attacks can result in fatal accidents. The computational time, cost, and robustness of encryption algorithms are important factors in low latency 5G‐enabled secure CAV networks. The presented chaotic Tangent‐Delay Ellipse Reflecting Cavity‐Map system and PieceWise Linear Chaotic Map‐based encryption on short messages exchanged in a CAV network provide both robustness and high speed encryption. In this work, we propose a 5G radio network architecture, which leverages multiple radio access technologies and utilizes Cloud Radio Access Network functionalities for privacy preserved and secure CAV networks. The proposed Vehicular Safety Message identifier algorithm meets transmission requirements with a high probability of 85% for low round trip delay of ≤50 milliseconds. The proposed chaos‐based encryption algorithm exhibits faster speeds with a computational time of 2 to 3 milliseconds, showcasing its lightweight properties ideal for time critical applications

Edge intelligence in private mobile networks for next generation railway systems

The integration of Private Mobile Networks (PMN) with edge intelligence is expected to play an instrumental role in realizing the next generation of industry applications. This combination collectively termed as Intelligent Private Networks (IPN) deployed within the scope of specific industries such as transport systems can unlock several use-cases and critical applications that in turn can address rising business demands. This article presents a conceptual IPN that hosts intelligence at the network edge employing emerging technologies that satisfy a number of Next Generation Railway System (NGRS) applications. NGRS use-cases along with their applications and respective beyond 5G (B5G) enabling technologies have been discussed along with possible future research and development directions that will allow these promising technologies to be used and implemented widely

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention